Fundz

Entact Bio reported raising $40.3 Million in an initial SEC Form D filing, from an offering of $39.9 Million

PRIVATEJan 31, 2024

Amount Raised

$40.3 Million

$40.3 Million sold, per SEC Form D (first sale Jan 19, 2024)

Round Type

Venture

WatertownBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as Entact Bio that raised within 45 days of this round, from Fundz verified event records.

  • Shape Memory Medical raised $38M (Series C) on March 4, 2024.
  • Shape Memory Medical raised $38M (Series C) on March 4, 2024.
  • Nocion Therapeutics raised $62M (Series B) on March 4, 2024.
  • Nektar Therapeutics raised $30M (Post-IPO Equity) on March 4, 2024.
  • Phagenesis raised $42M (Series D) on March 4, 2024.
  • Alumis raised $129M on March 4, 2024.

Who to call at Entact Bio, and when

A new round usually means Entact Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Entact Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Entact Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Entact Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Entact Bio

Location

65 Grove St. Suite 303

Watertown, South Dakota, United States

About

Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Entact Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsPaul P., Founder hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Entact Bio's next move

See what Strategic adds

Entact Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.